WuXi Biologics, a Contract Research, Development and Manufacturing Organisation (CRDMO), has entered into a strategic collaboration with Sinorda Biomedicine to develop and manufacture SND006, an innovative bispecific antibody being investigated for the treatment of Inflammatory Bowel Disease (IBD) and other autoimmune conditions.

Under the agreement, Sinorda Biomedicine will utilise WuXi Biologics’ integrated biologics development expertise and manufacturing capabilities to advance SND006 through preclinical pharmacology studies and ensure clinical supply, supporting a faster Investigational New Drug (IND) application process. SND006 is independently developed by Sinorda Biomedicine, which retains worldwide rights to the asset.

Commenting on the partnership, Dr. Chris Chen, CEO of WuXi Biologics, said, “The company has built extensive experience across hundreds of bispecific and multispecific antibody programmes, making it one of its fastest-growing segments. WuXi’s integrated technology platforms would help accelerate the development and manufacturing of SND006 while advancing the company’s mission to improve global access to innovative biologics.”

Sinorda Biomedicine has already completed in vitro functional validation studies for SND006 and plans to submit IND applications to China’s National Medical Products Administration (NMPA) and the US Food and Drug Administration (FDA) in 2026. Beyond SND006, the two companies intend to explore broader collaboration opportunities across Sinorda’s pipeline, spanning early-stage discovery through to clinical manufacturing.

Dr. Pingsheng Hu, Chairman and General Manager of Sinorda Biomedicine, said, “SND006 has the potential to be a best-in-class therapy for gastrointestinal and multiple autoimmune diseases. WuXi Biologics’ end-to-end CRDMO capabilities and strong track record in bispecific antibody development, noting that the collaboration is expected to expedite global IND filings and address significant unmet needs in autoimmune care.”